PDC Therapeutics is a next generation biotech company, developing targeted Polymer Drug Conjugates in the field of oncology. Our nanomedicine pipeline currently houses proprietary programs in various stages of preclinical and clinical development for treatment of cancer. Cooperating with multinational pharmaceutical companies through co-development programs, PDC therapeutics is supported by an industry experienced board of scientific and supervisory experts around the world. PDC is scientifically backed by RS Research, an academic spin-off which has developed a pioneering class of nanocarriers with targeting capability of different indications utilizing a plug & play technology approach for a “Cure with A Smile”.